Search Articles — Sudonull

https://sudonull.com/kalman-filter-as-observer-formulas-and-application

Analysis of the mathematical connection between the Kalman filter and the canonical observer. Prediction formulas, correction, example with a pump electric motor. For developers: implement a virtual tachometer in real-time systems.

https://sudonull.com/remycc-best-tcp-algorithms-from-mit-ai

Learn how Remy generates congestion control for TCP that surpasses Cubic and Compound TCP. ns-2 test results, application for dev. Optimize your network stack.

https://sudonull.com/aliro-protocol-digital-keys-standard-for-smart-home

Detailed analysis of the Aliro protocol — a new standard for access control in smart homes. Learn about the principles of operation, security, and practical application.

https://sudonull.com/laser-microscope-0-1-nm-for-oncology-and-ics

Learn about the laser microscope with 0.1 nm resolution: testing completed, application in cancer drug development and chip topology control. Technical details and comparisons.

https://sudonull.com/robot-cue7-toyota-breakthrough-in-physical-ai

Toyota tests machine vision and control through basketball robot CUE7. Learn about weight reduction, records, and applications in robotics. Read the analysis of implications for the industry.

https://ymaho.com/pediatric-dovato-ema-approves-application-for-hiv-therapy

EMA validated the application for pediatric Dovato (dolutegravir/lamivudine) for children from 2 years old. Learn how two-drug therapy is changing HIV treatment standards.

https://ymaho.com/ema-accepted-the-application-for-dovato-for-children-with-hiv

EMA validated the application for the use of Dovato in children from 3 months with HIV. Learn how this will change pediatric therapy and strengthen ViiV's position. Read the detailed analysis.

https://ymaho.com/pediatric-dovato-viiv-application-and-geopolitics-of-the-hiv-market

ViiV has submitted applications to the FDA and EMA for dispersible Dovato tablets for children. We analyze the strategy, patents, and implications. Find out who will win.

https://ymaho.com/study-of-the-ottava-robot-forte-results-and-fda-application

Scientists have completed the pivotal study of the Ottava robot (FORTE) and are preparing an FDA application. Learn about clinical data, zero conversions, and market prospects for robotic surgery.

https://ymaho.com/gene-therapy-for-deafness-otarmeni-ema-accelerated-review-2026

EMA accepted the application for gene therapy otarmeni for the treatment of hereditary deafness OTOF. Market analysis, forecasts, price and implications for the industry. Read.

https://ymaho.com/spacex-ipo-filing-for-75-billion-and-valuation-of-1-75-trillion

SpaceX filed an application for the largest IPO in history on Nasdaq up to $75 billion. Valuation $1.75 trillion, listing in June 2026. Analysis of the record, consequences and hidden details. Read more.

https://ymaho.com/intellia-crispr-therapy-fda-filing-for-lonvo-z-for-hae

Intellia has filed the world's first application for an in vivo CRISPR therapy, lonvo-z, for hereditary angioedema (HAE). 87% reduction in attacks, 62% attack-free. Risk, market, and forecast analysis. Read.

https://lrivo.com/linlithgow-rose-spfl-play-off-exclusion-due-to-licence

Linlithgow Rose miss SPFL play-offs after SFA bronze licence application declined. Brora Rangers face Edinburgh City in final. Learn why.

https://ymaho.com/ai-for-early-diagnosis-of-gallbladder-cancer-accuracy-92-97

PGIMER AI model analyzes ultrasound and detects gallbladder cancer at an early stage. Free application for hospitals. Data from The Lancet. Learn more.

https://ymaho.com/ipo-of-uznif-uzbekistan-s-entry-onto-the-london-stock-exchange-for-1-95-billion

Dual IPO of Uzbekistan's National Fund for $1.95 billion in Tashkent and London. GDR price — $25. Submit your application by May 12 and learn the placement details.